New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 20, 2013
09:13 EDTPCYCPharmacyclics price target raised to $165 from $110 at Wedbush
Wedbush raised its price target to $165 for Pharmacyclics on expectations breakthrough designation in MCL will lead to an earlier than expected approval for ibrutinib. The firm also expects significant off-label use of ibrutinib across hematological malignancies and keeps an Outperform rating on shares of Pharmacyclics.
News For PCYC From The Last 14 Days
Check below for free stories on PCYC the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for PCYC

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use